NCBiotech News

Humacyte, a regenerative medicine company based in Morrisville, has received a $9.9 million investment from the California Institute for Regenerative Medicine (CIRM) to support a clinical trial of its potential treatment for kidney disease.

Durham-based Bioventus, a fast-growing global orthobiologics company, has launched its second U.S. product for injection to relieve knee pain for osteoarthritis (OA) sufferers.

The latest company loans awarded by the North Carolina Biotechnology Center in the fourth quarter of FY 2016 bring to 189 the number of North Carolina bioscience companies that have received funding from the Center since its inception in 1984. The companies have received 276 loans totaling just under $34 million.

Four organizations -- BASF, Bayer, the Monsanto Fund and Syngenta – have provided $6,500 each to the North Carolina Biotechnology Center to support the summer 2016 Ag Biotech Industry in the Classroom program.

Durham-based Bioventus, a global orthobiologics company with growing sales revenues, has filed for a $150 million initial public offering (IPO) of stock.

Research Triangle Park-based medical diagnostics company BioMedomics has received approval from the Kenya Ministry of Health to sell Sickle SCAN, the company’s portable and quick-reporting test system for sickle cell disease (SCD) and sickle cell trait (SCT).

The North Carolina Biotechnology Center awarded more than $1.63 million in 18 loans and grants to propel the life science sector statewide during the quarter ended December 31, 2015.

Accolades flow freely to and through the North Carolina life science sector from around the world. Here are a few nice examples of "feathers added to our cap" in 2015.

Life science companies across North Carolina raised some $500 million in public and private financing in 2015.

The North Carolina Biotechnology Center awarded 27 loans and grants totaling about $1.8 million to companies and universities across the state during the final quarter of its 2014-2015 fiscal year ending June 30. Altogether, the Center made 82 loans and grants totaling $6,786,852 during the year just ended.

Companies and university researchers across North Carolina are harnessing compounds, microorganisms and unique materials to bring advanced wound healing, surgical devices and regenerative medicine to civilian and military markets.

NCBiotech awarded $1,683,000 in five loans and a grant during the second quarter of its 2014-2015 fiscal year. Its earlier loan recipients attract $24 million in external funding during the quarter and over $309 million in calendar year 2014.

Entegrion has received funding from NCBiotech -- and $88 million in contracts from various units in the U.S. Department of Defense (DOD) to help the RTP company keep building technologies that can save lives on battlefields by stopping blood loss and/or replacing lost blood components.

BioAgilytix Labs, a fast-growing Durham laboratory providing contract testing for pharmaceutical and biotechnology companies, has added two new high-efficiency testing devices to its arsenal.

G1 Therapeutics, a Chapel Hill company commercializing radiation-protection technology developed at the University of North Carolina at Chapel Hill, has raised $12.5 million in Series A funding.